HIV and AIDS

This page brings together the European Medicines Agency's (EMA) latest information on HIV and AIDS. It lists:

the newest and most recently updated medicines authorised for the treatment of HIV and AIDS in the European Union (EU);
any recent opinions on medicines against HIV and AIDS that are pending authorisation by the European Commission (EC);
EMA's latest HIV- and AIDS-related news announcements;
EMA's events on HIV- and AIDS-related topics.

How EMA supports the global response to HIV

EMA's factsheet shows how the Agency supports the global response to HIV through scientific evaluation, supervision and safety monitoring of medicines and active patient engagement.

New and recently updated medicines

Opinions pending EC decision

Latest news

Events of interest

List item

Tue 10 Nov

10/11/2015 - 10/11/2015

Expert meeting on paediatric development of fixed-dose combinations for the treatment of the human immunodeficiency virus (HIV)

As a requirement of the Paediatric Regulation, all new medicinal products developed for the...

HIV and AIDS

New and recently updated medicines

Darunavir Krka d.d. (Withdrawn)

Truvada (Authorised)

Stribild (Authorised)

Juluca (Authorised)

Biktarvy (Authorised)

Opinions pending EC decision

Triumeq

Genvoya

Latest news

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020

Vaginal ring to reduce the risk of HIV infection for women in non-EU countries with high disease burden

New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017

First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU

Updated advice on body fat changes and lactic acidosis with HIV medicines

Events of interest

Expert meeting on paediatric development of fixed-dose combinations for the treatment of the human immunodeficiency virus (HIV)